Abstracts Archive - Page 1184 of 2607 - ACR Meeting Abstracts

Abstract Number: 719 • 2019 ACR/ARP Annual Meeting
Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth
Hanyan Zou¹, Giada De Palma ², Premysl Bercik ², Elena Verdu ², Karen Beattie ² and Maggie Larche ², ¹McMaster University, Mississauga, ON, Canada, ²McMaster University, Hamilton, ON, Canada
Background/Purpose: The gastrointestinal tract (GIT) is commonly involved in SSc with up to 98% of patients reporting GIT manifestations. Small intestinal bacterial overgrowth (SIBO) is…
Abstract Number: 720 • 2019 ACR/ARP Annual Meeting
Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Robert Spiera¹, Nancy Dgetluck ², Bradley Bloom ², Barbara White ² and Christopher Denton ³, ¹Hospital for Special Surgery, New York, NY, ²Corbus Pharmaceuticals, Norwood, MA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: We report the baseline characteristics of a large cohort of diffuse cutaneous systemic sclerosis (dcSSc) patients enrolled in a Phase 3 trial of lenabasum,…
Abstract Number: 721 • 2019 ACR/ARP Annual Meeting
Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease
Marian Sidor¹, Roman Zuckerman ¹, Naomi Schlesinger ², Ross Sussman ³, Huma Jaleel Sabahath ⁴ and Vivien Hsu ⁵, ¹Rutgers-RWJ Medical School, New Brunswick, NJ, ²Rutgers Health- RWJ Medical School, New Brunswick, NJ, ³Rutgers-RWJ Medical School, East Brunswick, NJ 08816, NJ, ⁴AtlantiCare Regional Medical Center, Atlantic City, NJ, ⁵Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ
Background/Purpose: Lung involvement is the leading cause of death in systemic sclerosis (SSc) (1). Pulmonary function tests (PFTs) and chest high-resolution CT scan (HRCT) are…
Abstract Number: 722 • 2019 ACR/ARP Annual Meeting
The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Henriette Didriksen¹, Øyvind Molberg ², Håvard Fretheim ³, Einar Gude ², Vyacheslav Palchevskiy ⁴, Suzana Jordan ⁵, Torhild Garen ², Øyvind Midtvedt ², Arne Kristian Andreassen ², Oliver Distler ⁶, John Belperio ⁷ and Anna Maria Hoffmann-Vold ⁸, ¹Oslo University Hospital, Moss, Norway, ²Oslo University Hospital, Oslo, Norway, ³University Hospital Oslo, Oslo, Norway, ⁴2University of California Los Angeles, Los Angeles, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁷University of California Los Angeles, Los Angeles, ⁸Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major complication in systemic sclerosis (SSc) and is characterized by abnormalities in vascular pathways. In murine models of…
Abstract Number: 723 • 2019 ACR/ARP Annual Meeting
Diagnosis of Systemic Sclerosis: How and When
Cristina Sobrino¹ and Carlos De la Puente ², ¹Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disease regarding its clinical expression, evolution and forms of presentation. In spite of the lack of a disease…
Abstract Number: L15 • 2018 ACR/ARHP Annual Meeting
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
Anthony Sammel¹, Edward Hsiao², Geoffrey Schembri³, Katherine Nguyen⁴, Janice Brewer⁴, Leslie Schrieber⁵, Beatrice Janssen⁴, Peter Youssef⁶, Clare Fraser⁷, Elizabeth Bailey⁸, Dale Bailey⁸, Paul Roach⁸ and Rodger Laurent⁴, ¹Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Royal North Shore Hospital, St Leonards, Australia, ³Nuclear Medicine, Royal North Shore Hospital, St Leonards, Australia, ⁴Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁵Northern Clinical School, University of Sydney, Sydney, Australia, ⁶Royal Prince Alfred Hospital, Camperdown, Sydney, Australia, ⁷Save Sight Institute, Sydney, Australia, ⁸Royal North Shore Hospital, Sydney, Australia
Background/Purpose: The diagnostic accuracy of PET/CT against temporal artery biopsy (TAB) in patients suspected of having GCA has not been well studied. PET/CT has traditionally…
Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
Dawn McGuire¹, Neil Segal², Samy Metyas³, Hans Richard Barthel⁴, Meghan Miller⁵, David Rosen⁵ and Yoshi Kumagai⁵, ¹Orthotrophix, Incorporated, Oakland, CA, ²Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, KS, ³Medvin Clinical Research, Covina, CA, ⁴Barthel Clinic, Santa Barbara, CA, ⁵OrthoTrophix, Incorporated, Oakland, CA
Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: L19 • 2018 ACR/ARHP Annual Meeting
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Leslie Crofford¹, Dana Daily², Carol Vance³, Ruth Chimenti², Ericka Merriwether⁴, Miriam Bridget Zimmerman⁵, Jonathan Williams⁶, Meena Golchha⁶, Li Alemo Munters⁷, Katharine Geasland³, Barbara Rakel⁸ and Kathleen Sluka², ¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Physical Therapy, University of Iowa, Iowa City, IA, ³University of Iowa, Iowa City, IA, ⁴Physical Therapy, New York University, New York, NY, ⁵Public Health, University of Iowa, Iowa City, IA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Nursing, University of Iowa, Iowa City, IA
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition associated with pain and fatigue, especially during physical activity. Treatments designed to modulate central pain pathways to…
Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Thomas J. Schnitzer¹, Richard Easton², Shirley Pang³, Dennis Levinson⁴, Glenn Pixton⁵, Lars Viktrup⁶, Isabelle Davignon⁷, Mark T. Brown⁷, Kenneth M. Verburg⁷ and Christine R. West⁷, ¹Northwestern University, Chicago, IL, ²Michigan Orthopaedic & Spine Surgeons, Rochester Hills, MI, ³St. Jude Medical Center, Fullerton, CA, ⁴Chicago Clinical Research Institute, Chicago, IL, ⁵Pfizer, Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…
Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: L02 • 2018 ACR/ARHP Annual Meeting
Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
Julie J. Paik¹, Jemima Albayda², Eleni Tiniakou³, Andrew Koenig⁴ and Lisa Christopher-Stine⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Pfizer Inc, Collegeville, PA, ⁵Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy that primarily affects the muscle and skin. In refractory disease, it is common to fail 2 or…
Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Yusuf Yazici¹, Timothy E. McAlindon², Allan Gibofsky³, Nancy Lane⁴, Christian Lattermann⁵, Nebojsa Skrepnik⁶, Christopher Swearingen¹, Anita DiFrancesco¹, Jeymi Tambiah¹ and Marc Hochberg⁷, ¹Samumed, LLC, San Diego, CA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA, ³Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, ⁴Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Tucson Orthopaedic Institute, Tucson, AZ, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…
Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Paul Brogan¹, Gavin Cleary², Aimee O. Hersh³, Ozgur Kasapcopur⁴, Satyapal Rangaraj⁵, Rae S.M. Yeung⁶, Andrew Zeft⁷, Simone Melega⁸, Paul Brunetta⁹, Jennifer Cooper¹⁰, Pooneh Pordeli¹¹ and Patricia B. Lehane¹², ¹Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Alder Hey Children's Hospital, Liverpool, United Kingdom, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁶Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, ¹¹Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].